Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019860 | 0.87 | PDE4D (0.39) | CCNT1CDK2CDK9CCNK | |
| SCHEMBL3240478 | 0.86 | PIM1 (0.37) | PIM1PIM2CCNT1PTGER1NOS1 | |
| SCHEMBL3240488 | 0.86 | PIM1 (0.37) | PIM1PIM2CCNT1PTGER1NOS1 | |
| SCHEMBL2021429 | 0.82 | NUDT1 (0.46) | PIM1PIM2BRD4MAPK7CDK2 | |
| SCHEMBL2022499 | 0.76 | TSHR (0.39) | — | |
| SCHEMBL2022965 | 0.74 | PIM1 (0.35) | PIM1PIM2CCNT1PTGER1NOS1 | |
| SCHEMBL2021521 | 0.70 | PDE10A (0.45) | CDK2 | |
| SCHEMBL3236327 | 0.69 | CHRM3 (0.47) | PIM1NOS1NOS2CDK2CCNA2 | |
| SCHEMBL3236457 | 0.68 | MAPK1 (0.37) | PIM1CCNT1CDK2CDK9CDC7 | |
| SCHEMBL2020520 | 0.67 | KMT2A (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350027-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | PIM1 2743/4885PIM2 3252/4885CCNT1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.